Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 13/20 | 0.40 |
| ▸ | KCNH3 | Q9ULD8 | 3/20 | 0.38 |
| ▸ | YTHDF3 | Q7Z739 | 2/20 | 0.37 |
| ▸ | YTHDF1 | Q9BYJ9 | 2/20 | 0.37 |
| ▸ | YTHDF2 | Q9Y5A9 | 2/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | CLK2 | P49760 | 1/20 | 0.36 |
| ▸ | CLK3 | P49761 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30560029 | 1.00 | YTHDC1 (0.40) | YTHDC1KCNH3YTHDF3YTHDF1YTHDF2 | |
| SCHEMBL30560028 | 1.00 | YTHDC1 (0.40) | YTHDC1KCNH3YTHDF3YTHDF1YTHDF2 | |
| SCHEMBL20164341 | 0.79 | CCNE1 (0.44) | KCNH3CLK1CLK2CLK3DYRK1A | |
| Hydrochloric Acid SCHEMBL20164538 | 0.78 | CCNE1 (0.43) | KCNH3CLK1CLK2CLK3DYRK1A | |
| SCHEMBL30560031 | 0.75 | KMT2A (0.49) | YTHDC1YTHDF3YTHDF1YTHDF2 | |
| SCHEMBL16094346 | 0.75 | KMT2A (0.49) | YTHDC1YTHDF3YTHDF1YTHDF2 | |
| SCHEMBL20164561 | 0.74 | CYP1A2 (0.44) | YTHDC1YTHDF3YTHDF1YTHDF2 | |
| SCHEMBL20164757 | 0.74 | SLC29A1 (0.54) | YTHDC1 | |
| SCHEMBL20164718 | 0.73 | CDK2 (0.37) | KCNH3CLK4 | |
| SCHEMBL16094334 | 0.73 | YTHDC1 (0.61) | YTHDC1YTHDF3YTHDF1YTHDF2XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3316890-B1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME | NEURAD LTD (IL) | 2023-09-06 | — | — | EP | disclosed |
| US-10294228-B2 | Breathing control modulating compounds, and methods of making and using same | NEURAD LTD. (IL) | 2019-05-21 | — | — | US | disclosed |
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | NEURAD LTD. (IL) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | MTNR1B, CHRM3, PER2 | YTHDC1 2024/4885KCNH3 822/4885YTHDF3 1758/4885 |
| US-10294228-B2 | Breathing control modulating compounds, and methods of making and using same | MTNR1B, PDE3A, CHRM3 | YTHDC1 2085/4885KCNH3 1142/4885YTHDF3 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.